The Roche Group posted solid overall results in 2010
- Details
- Category: Roche
Group sales were stable in local currencies at 47.5 billion Swiss francs (-3% in Swiss francs; 1% in US dollars). The good underlying growth of both divisions compensated for the expected decline in Tamiflu sales and the impacts of healthcare reforms and austerity measures.
Novo Nordisk increased operating profit by 27% in 2010
- Details
- Category: Novo Nordisk
Sales increased by 19% in Danish kroner and by 13% measured in local currencies, which is slightly higher than the latest guidance of '11-12% growth in local currencies'. All regions contributed to growth measured in local currencies; North America was the main contributor with 62% share of growth measured in local currencies, followed by International Operations and Europe, contributing 24% and 12%, respectively.
Pfizer Reports Fourth-Quarter and Full-Year 2010 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2010. Since the acquisition of Wyeth was completed on October 15, 2009, fourth-quarter and full-year 2009 results reflect the legacy Wyeth operations from the acquisition date through Pfizer's domestic and international year-ends; results for all periods in 2010 reflect the legacy Wyeth operations.
Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG)
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) announced today that ongoing discussions with sanofi-aventis have progressed to the point where Genzyme's board has authorized the company to enter into a confidentiality agreement with sanofi-aventis in order to allow Sanofi to conduct due diligence.
Innovation drives Novartis to double-digit growth for 2010
- Details
- Category: Novartis
Net sales rose 14% (+14% cc) to USD 50.6 billion driven by strong growth in all businesses, including USD 2.4 billion from the consolidation of Alcon, Inc. (Alcon). Recently launched products provided USD 10.4 billion of net sales in the 2010 period, representing 21% of net sales compared to 16% in the 2009 period (excluding Alcon).
Bayer and Zydus Cadila sign Joint Venture Agreement
- Details
- Category: Bayer
Bayer HealthCare and the Indian company Zydus Cadila signed an agreement in Mumbai, India, to form the Joint Venture Company Bayer Zydus Pharma. With this newly established marketing and sales enterprise, Bayer aims to enhance its presence in the fast growing pharmaceutical market in India.
More Pharma News ...
- Bristol-Myers Squibb Delivers Solid Fourth Quarter Results
- AstraZeneca announced fourth quarter and full year results
- Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter
- Pediatric Exclusivity For PLAVIX®
- GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
- AstraZeneca Replies to FDA Complete Response Letter for BRILINTA
- Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®